We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Stock Moves -0.39%: What You Should Know
Read MoreHide Full Article
The most recent trading session ended with Astrazeneca (AZN - Free Report) standing at $66.26, reflecting a -0.39% shift from the previouse trading day's closing. This move was narrower than the S&P 500's daily loss of 1.11%. Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, lost 1.49%.
The pharmaceutical's stock has dropped by 1.01% in the past month, exceeding the Medical sector's loss of 4.56% and lagging the S&P 500's gain of 0.4%.
The investment community will be paying close attention to the earnings performance of Astrazeneca in its upcoming release. The company is forecasted to report an EPS of $1.06, showcasing a 45.21% upward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $14.26 billion, indicating a 18.57% upward movement from the same quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.11 per share and a revenue of $53.35 billion, indicating changes of +13.22% and +16.46%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Astrazeneca. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.41% rise in the Zacks Consensus EPS estimate. Astrazeneca presently features a Zacks Rank of #3 (Hold).
Looking at valuation, Astrazeneca is presently trading at a Forward P/E ratio of 16.18. This represents a premium compared to its industry's average Forward P/E of 13.89.
Also, we should mention that AZN has a PEG ratio of 1.19. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.47 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 138, this industry ranks in the bottom 46% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Stock Moves -0.39%: What You Should Know
The most recent trading session ended with Astrazeneca (AZN - Free Report) standing at $66.26, reflecting a -0.39% shift from the previouse trading day's closing. This move was narrower than the S&P 500's daily loss of 1.11%. Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, lost 1.49%.
The pharmaceutical's stock has dropped by 1.01% in the past month, exceeding the Medical sector's loss of 4.56% and lagging the S&P 500's gain of 0.4%.
The investment community will be paying close attention to the earnings performance of Astrazeneca in its upcoming release. The company is forecasted to report an EPS of $1.06, showcasing a 45.21% upward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $14.26 billion, indicating a 18.57% upward movement from the same quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.11 per share and a revenue of $53.35 billion, indicating changes of +13.22% and +16.46%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Astrazeneca. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.41% rise in the Zacks Consensus EPS estimate. Astrazeneca presently features a Zacks Rank of #3 (Hold).
Looking at valuation, Astrazeneca is presently trading at a Forward P/E ratio of 16.18. This represents a premium compared to its industry's average Forward P/E of 13.89.
Also, we should mention that AZN has a PEG ratio of 1.19. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.47 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 138, this industry ranks in the bottom 46% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.